Johnson & Johnson (JNJ)
Fundstrat's Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally
Fundstrat's Tom Lee returned to CNBC's Morning Call Sheet on Thursday, July 9, alongside JonesTrading's Mike O'Rourke and Vital Knowledge's Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names.
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.
Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism
Johnson & Johnson has delivered a 43% total return over 9 months, but I maintain a 'Hold' rating due to overvaluation concerns. JNJ's Q1 '26 showed 10% sales growth, but adjusted operational growth was only 5.3% and adjusted EPS declined 2.5% year-over-year. Management targets double-digit growth by the decade's end, yet consensus forecasts only ~6% EPS CAGR, and valuation multiples require aggressive growth assumptions.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
Eli Lilly (NYSE:LLY | LLY Price Prediction) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare.
Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
J&J's Innovative Medicine Business in Q2: Here's What to Watch
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
These 5 Passive Income Stocks Could Pay You For Life
Earned income demands your time. Passive income asks only that you stay invested.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug Tecvayli
JNJ gets a positive CHMP opinion for Tecvayli in combination with Darzalex SC for treating relapsed/refractory multiple myeloma after one prior therapy.
Johnson & Johnson (JNJ) Surges 4.0%: Is This an Indication of Further Gains?
Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
